Abbonarsi

POSTOPERATIVE THROMBOTIC COMPLICATIONS : Venous Thromboembolism: Deep-Vein Thrombosis and Pulmonary Embolism - 08/09/11

Doi : 10.1016/S0889-8537(05)70139-5 
Charl J. De Wet, MB, ChB *, Ronald G. Pearl, MD, PhD *

Riassunto

Autopsy findings indicate that 73% of pulmonary emboli diagnosed at autopsy were not detected clinically.70 The clinical diagnosis of venous thromboembolism is unreliable, and the first manifestation of the disease may be fatal pulmonary embolism. Patients may be totally asymptomatic, or they may have symptoms such as dyspnea, tachypnea, or chest pain, which may be dull and centrally located or pleuritic in nature. Patients often will have hypoxemia, and may initially also have hypocapnia secondary to hyperventilation. Wheezing may occur as a result of the release of emboli-associated inflammatory mediators such as serotonin. Patients may also have nonspecific signs, such as tachycardia or signs of right ventricular strain on ECG or on echocardiogram. The chest radiograph is often normal. At the other end of the spectrum is the patient who presents with sudden-onset cardiovascular collapse and pulseless electrical activity.

It is well known that surgery predisposes patients to venous thromboembolism. Less appreciated is the fact that they are at risk, not only in the immediate postoperative period, but even as late as 1 month postoperatively.11, 55 Deep vein thrombosis (DVT) and pulmonary embolism represent two aspects of the same disease process. Treatment and duration of treatment are usually the same in both instances.

Because diagnosis and treatment both confer significant risks to the patient, there has been an ongoing search to determine the optimal strategy for confirming, or excluding the diagnosis. Several factors have to be considered in the diagnostic work-up, such as the role of history and physical examination, and how it influences the final diagnosis. Laboratory data and other diagnostic tests should be evaluated for their sensitivity and specificity, cost-effectiveness, availability, expertise required in their interpretation, ease of performing, and patient comfort.

Advances have occurred in the field of anticoagulation with the introduction of low molecular weight heparins (LMWHs). Anticoagulation carries significant risks. The low therapeutic index of oral anticoagulants requires careful long-term monitoring, which in itself poses problems, and results in significant costs and inconvenience to patients. The role of inferior vena caval filters and surgical intervention also have associated significant costs and risks.

The identification and stratification of patients at risk for venous thromboembolism is of paramount importance in order to institute effective prophylaxis and treatment. Most patients who die from pulmonary embolism do so within 30 minutes of the acute event—too soon for anticoagulation to be effective.27 Despite numerous studies attesting to the efficacy and safety of prophylaxis, it is still underused.16

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Address reprint requests to Ronald G. Pearl, MD, PhD, Department of Anesthesia, Stanford University School of Medicine, 300 Pasteur Drive, Rm S268, Stanford, CA 94305-5117


© 1999  W. B. Saunders Company. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 17 - N° 4

P. 895-922 - dicembre 1999 Ritorno al numero
Articolo precedente Articolo precedente
  • SURGICAL FIELD HEMOSTASIS
  • Joseph Dooley, Peter J. Papadakos
| Articolo seguente Articolo seguente
  • PERIOPERATIVE ANTICOAGULATION AND THROMBOLYSIS IN CONGENITAL AND ACQUIRED COAGULOPATHIES
  • Leonardo Kapural, Juraj Sprung

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.